Horizon Therapeutics Public Stock Price, News & Analysis (NASDAQ:HZNP) Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$116.30▼$116.3050-Day Range$112.60▼$116.3052-Week Range$60.03▼$116.38VolumeN/AAverage Volume2.50 million shsMarket Capitalization$26.63 billionP/E Ratio62.19Dividend YieldN/APrice Target$116.83 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability Horizon Therapeutics Public MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside0.5% Upside$116.83 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings Growth35.08%From $4.19 to $5.66 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.64 out of 5 starsMedical Sector842nd out of 949 stocksPharmaceutical Preparations Industry395th out of 435 stocks 1.0 Analyst's Opinion Consensus RatingHorizon Therapeutics Public has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $116.83, Horizon Therapeutics Public has a forecasted upside of 0.5% from its current price of $116.30.Amount of Analyst CoverageHorizon Therapeutics Public has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for HZNP. Previous Next 0.0 Dividend Strength Dividend YieldHorizon Therapeutics Public does not currently pay a dividend.Dividend GrowthHorizon Therapeutics Public does not have a long track record of dividend growth. Previous Next 3.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHorizon Therapeutics Public has received a 34.65% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Nonsteroidal anti-inflammatory drugs", "Pegloticase", "Cysteamine", "Sodium phenylbutyrate", and "Inebilizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Horizon Therapeutics Public is -2.61. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for HZNP on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Horizon Therapeutics Public to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Horizon Therapeutics Public insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.20% of the stock of Horizon Therapeutics Public is held by insiders.Percentage Held by Institutions80.37% of the stock of Horizon Therapeutics Public is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Horizon Therapeutics Public are expected to grow by 35.08% in the coming year, from $4.19 to $5.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Horizon Therapeutics Public is 62.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.98.Price to Earnings Ratio vs. SectorThe P/E ratio of Horizon Therapeutics Public is 62.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 113.00.Price to Earnings Growth RatioHorizon Therapeutics Public has a PEG Ratio of 3.96. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHorizon Therapeutics Public has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Horizon Therapeutics Public Stock (NASDAQ:HZNP)Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.Read More HZNP Stock News HeadlinesNovember 16, 2023 | msn.comNasdaq On Horizon For Psyence Group: Psilocybin Therapeutics Division Forms New Business CombinationOctober 24, 2023 | chicago.suntimes.comHorizon Therapeutics cut jobs in Deerfield after Amgen acquisitionNovember 30, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 24, 2023 | msn.com350 Horizon Therapeutics workers to be laid off, mostly from Deerfield offices, following acquisition by AmgenOctober 6, 2023 | finance.yahoo.comRule 17(e) Announcement - Horizon Therapeutics plcOctober 5, 2023 | stocknews.com3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in OctoberOctober 5, 2023 | stockhouse.comRule 17(d) Announcement - Horizon Therapeutics plcOctober 5, 2023 | finance.yahoo.comRule 17(d) Announcement – Horizon Therapeutics plcNovember 30, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 2, 2023 | finance.yahoo.comHorizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023September 26, 2023 | benzinga.comBoard Member at Horizon Therapeutics Exercises Options Worth $2.31MSeptember 26, 2023 | finance.yahoo.comHorizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care IndustrySeptember 19, 2023 | finance.yahoo.comHorizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 ListSeptember 19, 2023 | finance.yahoo.comHealth care: FTC Chair Lina Khan to crack down on 'below radar' dealsSeptember 13, 2023 | finance.yahoo.comQ32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia AreataSeptember 5, 2023 | finance.yahoo.comHorizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of ArrangementSeptember 4, 2023 | benzinga.comHere's How Much $1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth TodaySeptember 1, 2023 | finanznachrichten.deHorizon Therapeutics plc and Amgen: Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close AcquisitionAugust 28, 2023 | finance.yahoo.comFTC suspends challenge to Amgen-Horizon Therapeutics dealAugust 26, 2023 | reuters.comUS FTC suspends challenge to block Amgen's $27.8 bln deal for Horizon TherapeuticsAugust 23, 2023 | finance.yahoo.comHorizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy GroupsAugust 16, 2023 | seekingalpha.comHorizon Therapeutics: Can Investors Profit From Amgen Deal Confusion?August 16, 2023 | seekingalpha.comImproved Outlook For Horizon Therapeutics And AmgenAugust 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Horizon Therapeutics (HZNP) and Biogen (BIIB)August 9, 2023 | markets.businessinsider.comHorizon Therapeutics (HZNP) Receives a Hold from H.C. WainwrightAugust 8, 2023 | finance.yahoo.comHorizon Therapeutics plc Reports Second-Quarter 2023 Financial ResultsAugust 4, 2023 | finance.yahoo.comAmgen raises full-year earnings and revenue outlookSee More Headlines Receive HZNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2023Today11/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:HZNP CUSIP44047T10 CIK1492426 Webwww.horizontherapeutics.com Phone(531) 772-2100Fax224-383-3001Employees2,115Year Founded2008Price Target and Rating Average Stock Price Target$116.83 High Stock Price Target$125.00 Low Stock Price Target$110.00 Potential Upside/Downside+0.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$1.87 Trailing P/E Ratio62.19 Forward P/E Ratio27.76 P/E Growth3.96Net Income$521.48 million Net Margins12.02% Pretax Margin12.18% Return on Equity20.46% Return on Assets11.52% Debt Debt-to-Equity Ratio0.48 Current Ratio4.27 Quick Ratio4.09 Sales & Book Value Annual Sales$3.63 billion Price / Sales7.34 Cash Flow$7.05 per share Price / Cash Flow16.49 Book Value$22.38 per share Price / Book5.20Miscellaneous Outstanding Shares228,990,000Free Float223,957,000Market Cap$26.63 billion OptionableOptionable Beta1.03 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Timothy P. Walbert (Age 56)Chairman, Pres & CEO Comp: $3.5MMr. Aaron L. Cox (Age 40)Exec. VP of Fin. & CFO Comp: $1.36MMr. Sean M. Clayton J.D. (Age 44)Exec. VP & Gen. Counsel Comp: $7.03MMr. Andy Pasternak (Age 52)Exec. VP & Chief Strategy Officer Comp: $1.4MDr. Elizabeth H.Z. Thompson Ph.D. (Age 48)Exec. VP of R&D Comp: $3.66MMr. Patrick McIlvenny (Age 44)Sr. VP & Chief Accounting Officer Ms. Tina E. VenturaSr. VP & Chief Investor Relations OfficerMr. Geoffrey M. Curtis (Age 48)Exec. VP of Corp. Affairs & Chief Communications Officer Ms. Keli WalbertExec. VP & Chief Marketing OfficerMs. Jane GonnermanSr. VP of Corp. Devel. & Chief of Staff, Office of the CEOMore ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZBristol-Myers SquibbNYSE:BMYAlnylam PharmaceuticalsNASDAQ:ALNYGenmab A/SNASDAQ:GMABBeiGeneNASDAQ:BGNEView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 684 shares on 11/30/2023Ownership: 0.012%Carmignac GestionBought 31,022 shares on 11/29/2023Ownership: 0.030%Deutsche Bank AGSold 1,551,165 shares on 11/24/2023Ownership: 0.318%Public Sector Pension Investment BoardSold 25,000 shares on 11/22/2023Ownership: 0.056%Walleye Capital LLCBought 2,900 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions Should I Buy Horizon Therapeutics Public Stock? HZNP Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Horizon Therapeutics Public was last updated on Tuesday, November 28, 2023 at 1:26 PM. Pros Here are some ways that investors could benefit from investing in Horizon Therapeutics Public Limited: The stock price of Horizon Therapeutics Public Limited has been steadily increasing in recent periods, indicating potential growth and positive investor sentiment. Horizon Therapeutics Public Limited has recently launched a new product, which has received positive reviews and is expected to contribute to the company's revenue growth. The company has a strong financial position, with a healthy balance sheet and positive cash flow, providing stability and potential for future investments and acquisitions. Horizon Therapeutics Public Limited has a diversified product portfolio, reducing the risk associated with relying on a single product or market segment. The company has a robust research and development pipeline, indicating potential for future product innovations and market expansion. Cons Investors should be bearish about investing in Horizon Therapeutics Public Limited for these reasons: The stock price of Horizon Therapeutics Public Limited has experienced volatility in recent periods, which may indicate uncertainty and potential risks for investors. The pharmaceutical industry is highly regulated, and changes in regulations or government policies could impact the company's operations and financial performance. Competition in the pharmaceutical industry is intense, and Horizon Therapeutics Public Limited may face challenges in maintaining market share and pricing power. The company's success is dependent on the successful development and commercialization of its pipeline products, which may involve significant research and development costs and regulatory hurdles. Investing in the stock market always carries inherent risks, and investors should carefully consider their risk tolerance and investment objectives before investing in Horizon Therapeutics Public Limited. HZNP Stock Analysis - Frequently Asked Questions Should I buy or sell Horizon Therapeutics Public stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares. View HZNP analyst ratings or view top-rated stocks. What is Horizon Therapeutics Public's stock price target for 2024? 7 Wall Street research analysts have issued twelve-month target prices for Horizon Therapeutics Public's stock. Their HZNP share price targets range from $110.00 to $125.00. On average, they predict the company's stock price to reach $116.83 in the next year. This suggests a possible upside of 0.5% from the stock's current price. View analysts price targets for HZNP or view top-rated stocks among Wall Street analysts. How were Horizon Therapeutics Public's earnings last quarter? Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.12 by $0.08. The biopharmaceutical company had revenue of $945 million for the quarter, compared to analyst estimates of $873.52 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 20.46% and a net margin of 12.02%. The firm's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the business posted $1.07 EPS. What ETFs hold Horizon Therapeutics Public's stock? ETFs with the largest weight of Horizon Therapeutics Public (NASDAQ:HZNP) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), First Trust Merger Arbitrage ETF (MARB), AltShares Merger Arbitrage ETF (ARB), VictoryShares Nasdaq Next 50 ETF (QQQN), ProShares Merger ETF (MRGR), Invesco Nasdaq Biotechnology ETF (IBBQ), Goldman Sachs Hedge Industry VIP ETF (GVIP) and Strategas Global Policy Opportunities ETF (SAGP). What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO? 70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees. What other stocks do shareholders of Horizon Therapeutics Public own? Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL). Who are Horizon Therapeutics Public's major shareholders? Horizon Therapeutics Public's stock is owned by a number of institutional and retail investors. Top institutional investors include Pentwater Capital Management LP (0.00%), Walleye Trading LLC (0.00%), Maven Securities LTD (0.00%), Soros Fund Management LLC (1.44%), Adage Capital Partners GP L.L.C. (1.28%) and Morgan Stanley (1.24%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Vikram Karnani and William F Daniel. View institutional ownership trends. Does Horizon Therapeutics Public have any subsidiaries? The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..Read More This page (NASDAQ:HZNP) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Horizon Therapeutics Public Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.